Sedative Effects of Low-Dose Risperidone in GAD Patients and Risk of Drug Interactions

View This PDF

NB: This article is only available as a PDF.

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Based on their results, Brawman-Mintzer et al.1 suggest that adjunctive risperidone at low doses may represent a useful tool in the management of symptomatic generalized anxiety disorder (GAD) patients. They found statistically significant improvements in core anxiety symptoms as demonstrated by greater reduction in Hamilton Rating Scale for Anxiety (HAM-A) total scores (p = .034) and HAM-A psychic anxiety factor scores (p = .047) compared with placebo. The authors also conclude that between-group differences in reported adverse events were not clinically significant.​

J Clin Psychiatry 2006;67(8):1307-1308 [letter]